Roivant Sciences Ltd (ROIV : NASDAQ)
Common Stock
$37.11
USD
+0.57 (1.56%)
Last updated: 2026-10-28
Follow ROIV
ROIV
Roivant Sciences Ltd
WealthAwesomePerformance
1 Day
+1.56%
1 Week
+0.84%
1 Month
+0.35%
YTD
+69.22%
Key Statistics
Market Cap
$26.39B
52W High
$42.50
52W Low
$19.30
P/E Ratio
-
50 Day MA
$36.65
200 Day MA
$31.29
Beta
1.10
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $36.43 | $37.13 | $36.13 | $37.11 | $37.11 | 5,477,388 |
| 10/27/2026 | $35.94 | $36.83 | $35.80 | $36.54 | $36.54 | 6,561,784 |
| 10/26/2026 | $36.66 | $36.91 | $35.66 | $36.05 | $36.05 | 9,133,820 |
| 10/23/2026 | $37.18 | $37.42 | $36.36 | $36.49 | $36.49 | 8,225,400 |
| 10/22/2026 | $36.68 | $38.49 | $36.68 | $37.45 | $37.45 | 13,451,162 |
| 10/21/2026 | $38.15 | $38.49 | $35.99 | $36.80 | $36.80 | 16,816,849 |
| 10/20/2026 | $35.00 | $35.52 | $34.38 | $34.92 | $34.92 | 3,670,739 |
| 10/19/2026 | $33.78 | $35.14 | $33.60 | $34.70 | $34.70 | 6,303,062 |
| 10/16/2026 | $34.12 | $34.12 | $33.23 | $33.53 | $33.53 | 4,923,400 |
| 10/15/2026 | $33.82 | $34.35 | $33.70 | $34.04 | $34.04 | 4,503,350 |
Analyst Price Targets
Based on 13 analysts covering ROIV · as of Oct 23, 2026
Wall Street analysts forecast ROIV stock price to rise 31.8% over the next 12 months.
Consensus
Strong Buy4.54 / 5.00
Avg. Target
US$48.91
+31.8% Upside
Previously US$48.27 on Oct 19, 2026
Current Price
US$37.11
Last close
Analyst Breakdown (13 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ROIV's historical volatility
30-Day Vol
35.7%
Annualized
90-Day Vol
45.6%
Annualized
Trend (90d)
+29.5%
Annualized drift
90d Mean
US$41.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$38.44 | US$33.98 – US$43.48 |
| 60 trading days | US$39.81 | US$33.44 – US$47.40 |
| 90 trading days | US$41.24 | US$33.31 – US$51.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Financials
- Revenue (TTM)
- $7.53M
- EBITDA
- $-1.34B
- Profit Margin
- 0.00%
- ROE (TTM)
- -8.52%
- EPS (Diluted)
- -0.53
- Book Value
- 5.86
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About ROIV.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
ROIV.US news timeline
1 article covering ROIV.US, most recent first
Latest